Silver Diamine Fluoride Trial Shows Promise for US Children’s Cavities

A Phase III trial involving 830 children under six in Michigan, New York and Iowa found that a single application of silver diamine fluoride (SDF) halted the progression of cavities in 54 % of treated teeth, compared with 22.5 % in the placebo group. The low‑cost liquid, which instantly arrests decay without drilling or anesthesia, darkens the treated portion of the tooth. Researchers highlighted its particular effectiveness on front teeth, where 42 % of lesions were arrested versus 26 % on back teeth.

The study, led by Professor Margherita Fontana of the University of Michigan School of Dentistry, provides the large‑scale U.S. data missing for FDA approval. SDF has been used for decades abroad and is on the WHO essential medicines list, but in the United States it is only cleared for treating tooth sensitivity. The trial’s results could pave the way for broader regulatory acceptance, offering a non‑invasive option for children, especially those with dental anxiety, special health needs, or limited access to dental care.